<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001746</url>
  </required_header>
  <id_info>
    <org_study_id>980102</org_study_id>
    <secondary_id>98-H-0102</secondary_id>
    <nct_id>NCT00001746</nct_id>
  </id_info>
  <brief_title>Screening for Inherited Heart Disease</brief_title>
  <official_title>Evaluation of Patients With Known or Suspected Inherited Heart Disease (Screening Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Genetically inherited heart diseases like hypertrophic cardiomyopathy (HCM) are conditions&#xD;
      affecting the heart passed on to family members by abnormalities in genetic information.&#xD;
      These conditions are responsible for many heart related deaths and illnesses.&#xD;
&#xD;
      Presently, there are several research studies being conducted in order to improve the&#xD;
      understanding of disease processes and symptoms associated with genetically inherited heart&#xD;
      diseases.&#xD;
&#xD;
      This study is designed to determine the eligibility of patients diagnosed with or suspected&#xD;
      to have inherited heart disease to participate in these research studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hypertrophic cardiomyopathy (HCM) and other inherited cardiac diseases are&#xD;
      being studied under several research protocols to determine their pathogenesis and clinical&#xD;
      manifestations. The purpose of this protocol is to determine the eligibility of patients with&#xD;
      known or suspected inherited heart conditions for our research protocols.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date>April 2003</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Heart Disease</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Subjects and family members known or suspected to have inherited a cardiac disease such as&#xD;
        HCM.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Patients with cardiac conditions that are not known to be inherited.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Heart, Lung and Blood Institute (NHLBI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med. 1987 Mar 26;316(13):780-9. doi: 10.1056/NEJM198703263161305. No abstract available.</citation>
    <PMID>3547130</PMID>
  </reference>
  <reference>
    <citation>Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation. 1995 Oct 1;92(7):1680-92. doi: 10.1161/01.cir.92.7.1680.</citation>
    <PMID>7671349</PMID>
  </reference>
  <reference>
    <citation>Solomon SD, Jarcho JA, McKenna W, Geisterfer-Lowrance A, Germain R, Salerni R, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy is a genetically heterogeneous disease. J Clin Invest. 1990 Sep;86(3):993-9. doi: 10.1172/JCI114802.</citation>
    <PMID>1975599</PMID>
  </reference>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>March 4, 2008</last_update_submitted>
  <last_update_submitted_qc>March 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2008</last_update_posted>
  <keyword>Hypertrophic Cardiomyopathy</keyword>
  <keyword>HCM</keyword>
  <keyword>Evaluation for Research</keyword>
  <keyword>Medical Advice</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

